

Neuland Laboratories Limited Sanali Info Park, 'A' Block, Ground Floor, 8-2-120/113 Road No. 2, Banjara Hills Hyderabad – 500 034. Telangana, India.

Tel: 040 30211600 / 23551081 Fax: 040 30211602 Email: neuland@neulandlabs.com www.neulandlabs.com

November 5, 2018

To B S E Limited Phiroze Jeejeebhoy Towers, 25th Floor, Dalal Street, Mumbai - 400 001

To
The National Stock Exchange of India Ltd
Exchange Plaza,
Bandra Kurla Complex
Bandra (E)
Mumbai - 400 001

Scrip Code: 524558

Scrip Code: NEULANDLAB

Series: EQ

Dear Sirs,

Sub: Compliance with Regulation 47 (1) (b) of the SEBI Listing Regulations, 2015

Please find attached herewith copies of the newspaper publication of Un-audited financial results for the quarter ended September 30, 2018, published in Financial Express and Andhra Prabha on November 3, 2018, for your reference.

Thanking you,

Yours faithfully, For Neuland Laboratories Limited

Sarada Bhamidipati Company Secretary

Encl: as above



NEULAND LABORATORIES LIMITED

(CIN: L85195TG1984PLC004393)
Regd. office: Sanali Info park, 'A' Block, Ground floor 8-2-120/113, Road No.2, Banjara Hills, Hyderabad-500034



STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30 SEPTEMBER 2018

SI. No.	Particulars	Quarter Ended			Half Year Ended		Year Ended
		30.09.2018 (Unaudited)	30.06.2018 (Unaudited)	30.09.2017 (Unaudited)	30.09.2018 (Unaudited)	30.09.2017 (Unaudited)	31.03.2018 (Audited)
2 3 4 5 6	Revenue from operations Net profit for the period (before tax and exceptional items) Net profit for the period before tax Net profit for the period after tax Total comprehensive income for the period Paid-up Equity Share Capital (Face value - ₹ 10 each)	16,874.08 529.87 529.87 440.13 481.95 1,290.05	55.01 55.01 41.26 44.94	12,991.46 390.39 390.39 240.06 234.51 895.49	32,269.83 584.88 584.88 481.39 526.89 1,290.05	24,707.13 476.18 476.18 301.90 290.80 895.49	52,916.15
3	Other equity Equity suspense account Earnings Per Share (of ₹ 10 each) (In absolute ₹ terms) (a) Basic (b) Diluted	3.43 3.43	0.35 0.35	2.15 2.15	3.90 3.90	2.71	23,497.51 31,084.99 10.59 10.59

The above is an extract of the detailed format of Unaudited Financial Results for the quarter and half year ended September 30, 2018 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Unaudited Financial Results are available on the Stock Exchange websites and on the website of the Company i.e. www.neulandlabs.com By Order of the Board

For Neuland Laboratories Limited

Dr. D.R.Rao Chairman & Managing Director (DIN 00107737)

Place: Hyderabad Date: 2 November 2018

FINANCIAL EXPRESS

SATURDAY, NOVEMBER 3, 2018

NEULAND LABORATORIES LIMITED
(CIN: L85195TG1984PLC004393)

Regd. office: Sanali Info park, 'A' Block, Ground floor 8-2-120/113, Road No.2, Banjara Hills, Hyderabad-500034



STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30 SEPTEMBER 2018

(Almount in taxes of ₹, unless otherwise stated									
SI.	. Particulars	Quarter Ended			Half Year Ended		Year Ended		
No.		30.09.2018 (Unaudited)	30.06.2018 (Unaudited)	30.09.2017 (Unaudited)	(Unaudited)	30.09.2017 (Unaudited)	31.03.2018 (Audited)		
1	Revenue from operations	16.874.08	15,395.75	12,991.46	32,269.83	24,707.13	52,916.15		
2	Net profit for the period (before tax and exceptional items)	529.87	55.01	390.39	584.88	476.18			
3	Net profit for the period before tax	529.87	55.01	390.39	584.88	476.18			
	Net profit for the period after tax	440.13	41.26	240.06	481.39	301.90			
5	Total comprehensive income for the period	481.95	44.94	234.51	526.89	290.80	1,200.36		
6	Paid-up Equity Share Capital (Face value - ₹ 10 each)	1,290.05	1,290.05	895.49	1,290.05	895.49	895.49		
7	Other equity						23,497.51		
8	Equity suspense account						31,084,99		
9	Earnings Per Share (of ₹ 10 each) (In absolute ₹ terms)	Con St.					31,004.77		
	(a) Basic	3.43	0.35	2.15	3.90	2.71	10.59		
	(b) Diluted	3.43		2.15	3.90	2.71	10.59		

with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Unaudited Financial Results are available on the Stock Exchange websites and on the website of the Company i.e. www.neulandlabs.com

> Dr. D.R.Rao Chairman & Managing Director (DIN 00107737)

Note: The above is an extract of the detailed format of Unaudited Financial Results for the quarter and half year ended September 30, 2018 filed By Order of the Board For Neuland Laboratories Limited

Place: Hyderabad Date: 2 November 2018